Obstructive sleep apnea

No additional finding was selected from these checked sources. Coverage remains incomplete; this is not a full-topic “no news” conclusion.

Remaining gaps: Read current canonical scope, shared summaries, state and assigned topic notes. Bounded registry discovery covered July 18–October 16, 2026; prior October 13 findings were deduplicated. Full-topic successful-check dates remain unchanged.; Retrieved all 148 records across 2 pages of the bounded ClinicalTrials.gov query, plus 6 named records. Selected relevant new/changed protocols were appraised; downloading all records does not establish exhaustive safety/results review.; Europe PMC original-literature discovery failed with HTTP 503 for this topic. Targeted primary-source web searches supplied a partial fallback. Worldwide literature, regulators, international registries and complete original conference/podcast recordings remain incomplete.; The new condition baseline remains incomplete. Preceding 90-day registry discovery and selected inherited pivotal context were checked; the full older clinical, label and behavioral/device evidence corpus has not been completed.; AD109 CHEST October 20 presentations remain future scheduled events; October 12 announcement was deduplicated. Named PAP-related metabolic and oral combination protocols were refreshed. No new AD109 effect or FDA decision inferred. The newly registered retrospective athlete CPAP study was not promoted as broad clinical evidence; comprehensive device/harms validation remains incomplete.

Informal-source coverage: Targeted oral-apnea/device informal searches did not provide a new attributable development signal selected. Existing AD109 scheduled presentation and approval-date speculation were deduplicated. Full original sleep conferences and device-access recordings remain incomplete.

Full coverage record.

Development / U.S. status: Investigational combination of aroxybutynin and atomoxetine. The inherited September 8 source gives an FDA action target of February 28, 2027; a filing acceptance, proposed brand or target date is not approval.

Evidence / limitations: SynAIRgy phase 3 (NCT05813275) randomized 646 adults with mild-to-severe OSA who could not tolerate or refused PAP for 26 weeks. The main analysis found an AHI difference of −4.0 events/hour (95% CI −6.4 to −1.6) and model-estimated reductions of 44.1% versus 17.6%. Oxygenation improved; PROMIS-Fatigue did not significantly improve. Adverse-event discontinuation was 21.2% versus 3.1%. The sponsor's 55.6% headline uses a different, on-treatment analysis. This is physiological efficacy with tolerability limitations, not proof of cardiovascular benefit.

Next milestone: February 28, 2027 FDA decision target, inherited from the September 8 source. Published trial · September 8 SEC-filed status · Full original notes.

Established practice: AASM's 2017 guideline supports laboratory polysomnography (PSG), or technically adequate home sleep apnea testing (HSAT) for uncomplicated adults with signs/symptoms indicating increased moderate-to-severe OSA risk. A negative, inconclusive or technically inadequate home test should lead to PSG. PSG is preferred with significant cardiorespiratory disease, hypoventilation risk, chronic opioid use, stroke or severe insomnia.

Evidence / limitations: Most conventional home tests do not record EEG, eye-movement and muscle-staging channels. Their respiratory event index (REI) uses monitoring/recording time rather than measured sleep time, so it is distinct from sleep-hour AHI and can underestimate severity. Some home systems use different sensors or stage estimates; not all home tests are equivalent. Detection, diagnosis and treatment selection remain separate.

Next milestone: Prospective validation, missed cases/false alerts and demonstrated management or patient benefit; no common firm date. AASM diagnostic guideline, 2017 · AASM home-testing position statement.

Established practice: PAP holds the airway open with pressure. AASM 2019 strongly recommends PAP for adults with OSA and excessive sleepiness; conditional recommendations also address impaired sleep-related quality of life and comorbid hypertension. Mask fit, ongoing use and follow-up are part of practical effectiveness.

Evidence / limitations: Breathing control, sleepiness, quality of life and treatment burden require separate assessment. The guideline found insufficient/inconclusive evidence to recommend or withhold PAP solely to reduce cardiovascular events or mortality in non-sleepy adults; this is not a blanket claim that PAP lacks cardiovascular value.

Next milestone: Better adherence, phenotype-specific clinical outcomes and long-term comparative evidence; no common firm date. AASM PAP guideline, 2019 · NIH CPAP explanation.

Established practice: AASM/AADSM 2015 recommends considering prescription oral appliances for people intolerant of CPAP or preferring an alternative. A custom titratable appliance should be fitted and followed by a qualified dentist.

Evidence / limitations: Verify response through follow-up sleep testing and monitor bite/dental changes. Reduced breathing-event burden or subjective sleepiness is not demonstrated cardiovascular-event reduction. An oral appliance is not interchangeable with an unsupervised consumer mouthguard.

Next milestone: Long-term dental/bite safety, adherence and clinical effectiveness by phenotype; no common firm date. AASM/AADSM guideline, 2015.

Development / population: Devices that discourage back-sleeping are relevant when events are substantially worse in the supine position, not universally across OSA.

Evidence / limitations: A sham-controlled 120-person study (NCT04153240; published March 13, 2026) found an AHI difference of −4.41 events/hour (95% CI −7.77 to −1.06) at three months. Sleep quality improved, while Epworth sleepiness did not significantly improve. Median baseline AHI was 12.8; the effect must not be ranked directly against trials enrolling more severe or different populations. This is historical baseline, not a new October readout.

Next milestone: Durability, adherence and patient-centered outcomes; no firm new date. Primary trial.

Established approaches / U.S. status: Selected options include tonsil/tissue surgery, jaw advancement and implanted hypoglossal nerve stimulation. FDA's June 8, 2023 Inspire expansion applies to selected adults with moderate-to-severe OSA who cannot use or tolerate PAP and meet anatomical/eligibility criteria. It is not a universal replacement for PAP.

Evidence / limitations: Assess event burden, daily function and quality of life alongside procedure, implant and device risks; selection and anatomy matter.

Next milestone: Better comparative selection, durability and longer-term outcomes; no common firm date. FDA Inspire indication expansion · NIH treatment overview, updated January 9, 2025.

Development / U.S. status: FDA approved Zepbound on December 20, 2024 for moderate-to-severe OSA in adults with obesity, alongside reduced-calorie diet and increased physical activity. This is historical approval context, not a new October action.

Evidence / limitations: Two 52-week randomized trials studied separate groups using PAP and not using PAP. FDA describes the AHI improvement as likely related to weight reduction. This indication does not apply to every person with OSA, or establish that PAP should be stopped. Keep weight, AHI, oxygen burden, sleepiness and cardiovascular outcomes distinct.

Next milestone: Durability, clinical outcomes and treatment-selection evidence; no common firm new date. FDA approval · SURMOUNT-OSA primary trial · Metabolic-therapy notes.

OSA and insomnia are different conditions, and PAP does not necessarily resolve coexisting insomnia. In a 2019 trial of 145 participants with both, CBT-I before CPAP improved insomnia and average nightly PAP use by 61 minutes (95% CI 9–113) over six months; daytime-impairment differences were not significant at six months. Keep treating the airway and treating insomnia as linked, distinct questions. Primary trial · Insomnia notes.